A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEO Pharma

Criteria

Inclusion Criteria:

• Age 18-55 years

• Atopic dermatitis of 850-1700cm2

• In good health

Criteria for exclusion:

• Co-morbid conditions

• Hepatic dysfunction

• Clinical infection

• Immunocompromised status

• Clinically significant illness

• Use of immunomodulating treatment

• Medications related to respiratory system or to heart rhythm